| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1997;63:74-77
© 1997 The Society of Thoracic Surgeons
-Aminocaproic Acid on Cytokine-Induced Inducible Nitric Oxide Synthase Expression
Pulmonary and Critical Care Medicine Section, Department of Internal Medicine, and Department of Anesthesiology, University of Nebraska Medical Center; and Research Service, Omaha Veterans Affairs Medical Center, Omaha, Nebraska
Accepted for publication August 2, 1996.
Background. Cell expression of inducible nitric oxide synthase (iNOS) is increased by cytokines, resulting in high endogenous levels of nitric oxide. Expression of iNOS has been implicated in organ injury, including myocardial reperfusion injury. Serine protease inhibitors reduce cytokine-induced iNOS expression. The protease inhibitors aprotinin and 
-aminocaproic acid (EACA), used to reduce blood loss after cardiac operations, were evaluated in vitro on cytokine-induced iNOS expression and nitric oxide production.
Methods. A murine bronchial epithelial cell line was stimulated with a mixture of cytokines (tumor necrosis factor-
, interleukin-1ß, and interferon-
) with or without aprotinin or EACA. The resultant iNOS expression was asured by northern blot analysis, and nitric oxide production was assessed by cell supernatant nitrite levels.
Results. Nitrite concentrations in the supernatant were significantly increased after cytokine stimulation; they were not affected by any concentration of EACA but were significantly (p < 0.05) reduced by aprotinin. Aprotinin significantly (p < 0.05) reduced cytokine-induced iNOS expression, whereas EACA had no effect.
Conclusions. Aprotinin, but not EACA, reduces cytokine-induced nitric oxide production by inhibition of iNOS expression. Because increased endogenous nitric oxide levels secondary to iNOS activation have been implicated in organ injury, aprotinin may have clinical benefit compared with EACA when used for cardiac operations.
This article has been cited by other articles:
|
|
 |
|
  D. T. Mangano, Y. Miao, A. Vuylsteke, I. C. Tudor, R. Juneja, D. Filipescu, A. Hoeft, M. L. Fontes, Z. Hillel, E. Ott, et al. Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft Surgery JAMA, February 7, 2007; 297(5): 471 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Mangano, I. C. Tudor, C. Dietzel, and the Multicenter Study of Perioperative Ischemia Re The Risk Associated with Aprotinin in Cardiac Surgery N. Engl. J. Med., January 26, 2006; 354(4): 353 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Pearl, D. P. Nelson, S. M. Schwartz, and P. B. Manning First-stage palliation for hypoplastic left heart syndrome in the twenty-first century Ann. Thorac. Surg., January 1, 2002; 73(1): 331 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Landis, G. Asimakopoulos, M. Poullis, D. O. Haskard, and K. M. Taylor The antithrombotic and antiinflammatory mechanisms of action of aprotinin Ann. Thorac. Surg., December 1, 2001; 72(6): 2169 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Hill The Inflammatory Response to Cardiopulmonary Bypass-- Should It Be Treated? Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 229 - 235. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Ulker, M. G. Cinar, U. Bayraktutan, and A. Evinc Aprotinin impairs endothelium-dependent relaxation in rat aorta and inhibits nitric oxide release from rat coronary endothelial cells Cardiovasc Res, June 1, 2001; 50(3): 589 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Royston Hemostatic Drugs in Prothrombotic or Hypercoagulable States Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 376 - 394. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
